宫颈癌组织中Survivin、ICAM-3的表达及与放疗敏感性的关系被引量：2

Expression of Survivin and ICAM-3 in Cervical Cancer Tissues and Their Relationship with Radiotherapy Sensitivity

下载PDF

导出

摘要目的探究宫颈癌组织中Survivin、ICAM-3的表达及与放疗敏感性的关系。方法选取宫颈癌患者50例,根据放疗敏感性的不同将患者分为放疗敏感组(n=28)和放疗抵抗组(n=22)。采用免疫组化分析宫颈癌患者的Survivin、ICAM-3水平,比较其和临床病理特征及放疗敏感性的关系。结果放疗敏感组和放疗抵抗组的FIGO分期差异无统计学意义(P>0.05),放疗抵抗组肿瘤的分化程度更低,肿瘤直径更大,差异有统计学意义(P<0.05)。放疗敏感组Survivin、ICAM-3的阳性表达率明显低于放疗抵抗组,差异有统计学意义(P<0.05)。多因素分析结果发现,分化程度、肿瘤直径与放疗敏感性无关(P>0.05),Survivin、ICAM-3表达水平与放疗敏感性有关(P<0.05)。结论宫颈癌患者Survivin、ICAM-3水平以及临床病理特征与放疗敏感性有关,可为今后探索宫颈癌的预后指标提供一定的参考依据。 Objective To investigate the expression of Survivin and ICAM-3 in cervical cancer tissues and their relationship with radiotherapy sensitivity.Methods 50 patients with cervical cancer were divided into radiotherapy sensitive group(n=28) and radiotherapy resistant group(n=22).Immunohistochemistry was used to analyze Survivin and ICAM-3 levels in patients with cervical cancer, and the relationship between survivin and ICAM-3 levels and clinicopathological features and radiotherapy sensitivity were compared.Results There was no significant difference in FIGO stage between radiotherapy sensitive group and radiotherapy resistant group(P>0.05).The tumor differentiation degree and tumor diameter of radiotherapy resistant group were lower, and the difference was statistically significant(P<0.05).The positive expression rates of Survivin and ICAM-3 in the radiotherapy sensitive group were significantly lower than those in the chemotherapy resistance group(P<0.05).The results of multivariate analysis showed that the degree of differentiation and tumor diameter were not related to the sensitivity of radiotherapy(P>0.05),while the expression levels of Survivin and ICAM-3 were related to the sensitivity of radiotherapy(P<0.05).Conclusion The levels of Survivin, ICAM-3 and clinicopathological features in patients with cervical cancer are related to the sensitivity of radiotherapy, which provides a certain reference for exploring the prognostic indicators of cervical cancer in the future.

作者朱瑞霞侯永利李齐羽齐林 ZHU Ruixia;HOU Yongli;LI Qiyu(Zhengzhou Yihe hospital,Zhengzhou,450000)

机构地区河南省郑州颐和医院

出处《实用癌症杂志》 2023年第1期21-24,共4页 The Practical Journal of Cancer

关键词宫颈癌组织 SURVIVIN ICAM-3 放疗敏感性 Cervical cancer Tissue Survivin ICAM-3 Radiotherapy sensitivity

分类号 R737.33 [医药卫生—肿瘤]

引文网络
相关文献

参考文献1

1宫颈癌及癌前病变规范化诊疗指南(试行)[J].中国医学前沿杂志（电子版）,2013,5(8):40-49. 被引量：217

二级参考文献27

1Jemal A,Siegel R,Ward E. Cancer Statistics,2007[J].{H}CA-A Cancer Journal for Clinicians,2007.43-66.
2Howe HL,Wu X,Ries LA. Annual report to the nation on the status of cancer,1975-2003,featuring cancer among U.S.Hispanic/Latino populations[J].{H}CANCER,2006,(08):1711-1742.
3Sherman ME,Wang SS,Carreon J. Mortality trends for cervical squamous and adenocarcinoma in the United States.Relation to incidence and survival[J].{H}CANCER,2005,(06):1258-1264.
4Parkin DM,Bray F,Ferlay J. Global cancer statistics,2002[J].{H}CA-A Cancer Journal for Clinicians,2005.74-108.
5Kamangar F,Dores GM,Anderson WF. Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world[J].{H}Journal of Clinical Oncology,2006,(14):2137-2150.
6Villa LL,Costa RL,Petta CA. Prophylactic quadrivalent human papillomavirus(types 6,11,16,and 18)L1 virus-like particle vaccine in young women:a randomized double-blind placebo-controlled multicentre phase II efifcacy trial[J].{H}LANCET ONCOLOGY,2005.271-278.
7Ault KA,Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2,grade 3,and adenocarcinoma in situ:a combined analysis of four randomised clinical trials[J].{H}LANCET,2007,(9576):1861-1868.
8FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J].{H}New England Journal of Medicine,2007,(19):1915-1927.
9Arbyn M,Dillner J. Review of current knowledge on HPV vaccination：an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening[J].{H}Journal of Clinical Virology,2007,(03):189-197.
10American College of Obstetricians and Gynecologists. ACOG practice bulletin.Diagnosis and treatment of cervical carcinomas.Number 35,May 2002[J].{H}International Journal of Gynecology & Obstetrics,2002.79-91.